Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location

Clinical and Translational Gastroenterology

Volumn 7, Issue 11, 2016, Pages

  Mima, Kosuke ^a   Cao, Yin ^b,c   Chan, Andrew T ^b,d   Qian, Zhi Rong ^a   Nowak, Jonathan A ^d   Masugi, Yohei ^a   Shi, Yan ^a   Song, Mingyang ^b,c   Da Silva, Annacarolina ^a   Gu, Mancang ^a   Li, Wanwan ^a   Hamada, Tsuyoshi ^a   Kosumi, Keisuke ^a   Hanyuda, Akiko ^a   Liu, Li ^a   Kostic, Aleksandar D ^b,c,e   Giannakis, Marios ^a,d,e   Bullman, Susan ^a,e   Brennan, Caitlin A ^c   Milner, Danny A ^c,d   Baba, Hideo ^f   Garraway, Levi A ^a,d,e   Meyerhardt, Jeffrey A ^a   Garrett, Wendy S ^a,c,e   Huttenhower, Curtis ^b,c,e   Meyerson, Matthew ^a,e   Giovannucci, Edward L ^c,d   Fuchs, Charles S ^a,d   Nishihara, Reiko ^a,c   Ogino, Shuji ^a,c,d   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA;

AGED; ARTICLE; ASCENDING COLON; CARCINOGENESIS; CECUM; COLORECTAL CARCINOMA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DESCENDING COLON; FEMALE; FUSOBACTERIUM NUCLEATUM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM; RETROSPECTIVE STUDY; SIGMOID; SPLENIC FLEXURE; TRANSVERSE COLON; TUMOR LOCALIZATION; UNITED STATES;

EID: 84994644413     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2016.53     Document Type: Article

References (67)

1. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014; 12: 661-672.
2. Keku TO, Dulal S, Deveaux A et al. The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2015; 308: G351-G363.
3. Ericsson AC, Akter S, Hanson MM et al. Differential susceptibility to colorectal cancer due to naturally occurring gut microbiota. Oncotarget 2015; 6: 33689-33704.
4. Dejea CM, Wick EC, Hechenbleikner EM et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 2014; 111: 18321-18326.
5. Belcheva A, Irrazabal T, Robertson SJ et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 2014; 158: 288-299.
6. Dulal S, Keku TO. Gut microbiome and colorectal adenomas. Cancer J 2014; 20: 225-231.
7. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014; 15: 317-328.
8. Gur C, Ibrahim Y, Isaacson B et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015; 42: 344-355.
9. Kostic AD, Chun E, Robertson L et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14: 207-215.
10. Rubinstein MR, Wang X, Liu W et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013; 14: 195-206.
11. Kostic AD, Gevers D, Pedamallu CS et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292-298.
12. Castellarin M, Warren RL, Freeman JD et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299-306.
13. McCoy AN, Araujo-Perez F, Azcarate-Peril A et al. Fusobacterium is associated with colorectal adenomas. PLoS One 2013; 8: e53653.
14. Tahara T, Yamamoto E, Suzuki H et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014; 74: 1311-1318.
15. Ito M, Kanno S, Nosho K et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015; 137: 1258-1268.
16. Mima K, Sukawa Y, Nishihara R et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 2015; 1: 653-661.
17. Nosho K, Sukawa Y, Adachi Y et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22: 557-566.
18. Li YY, Ge QX, Cao J et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol 2016; 22: 3227-3233.
19. Iacopetta B. Are there two sides to colorectal cancer Int J Cancer 2002; 101: 403-408.
20. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol 2004; 88: 261-266.
21. Carethers JM. One colon lumen but two organs. Gastroenterology 2011; 141: 411-412.
22. Yamauchi M, Morikawa T, Kuchiba A et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854.
23. Phipps AI, Buchanan DD, Makar KW et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012; 21: 1792-1798.
24. Rosty C, Young JP, Walsh MD et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One 2013; 8: e65479.
25. Phipps AI, Limburg PJ, Baron JA et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015; 148: 77-87 e72.
26. Cummings JH, Pomare EW, Branch WJ et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-1227.
27. Hayashi H, Takahashi R, Nishi T et al. Molecular analysis of jejunal, ileal, caecal and rectosigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. J Med Microbiol 2005; 54: 1093-1101.
28. Li X, LeBlanc J, Truong A et al. A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface. PLoS One 2011; 6: e26542.
29. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol 2014; 14: 667-685.
30. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival. N Engl J Med 2012; 367: 1596-1606.
31. Nishihara R, Wu K, Lochhead P et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369: 1095-1105.
32. Mima K, Nishihara R, Qian ZR et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016 in press.
33. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96.
34. Irahara N, Nosho K, Baba Y et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010; 12: 177-183.
35. Ogino S, Kawasaki T, Brahmandam M et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006; 8: 209-217.
36. Ogino S, Kawasaki T, Kirkner GJ et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007; 9: 305-314.
37. Ogino S, Kawasaki T, Brahmandam M et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7: 413-421.
38. Imamura Y, Lochhead P, Yamauchi M et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014; 13: 135.
39. Nosho K, Kawasaki T, Ohnishi M et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534-541.
40. Liao X, Morikawa T, Lochhead P et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18: 2257-2268.
41. Khashab MA, Pickhardt PJ, Kim DH et al. Colorectal anatomy in adults at computed tomography colonography: normal distribution and the effect of age, sex, and body mass index. Endoscopy 2009; 41: 674-678.
42. Yamauchi M, Lochhead P, Morikawa T et al. Colorectal cancer: a tale of two sides or a continuum Gut 2012; 61: 794-797.
43. Jess P, Hansen IO, Gamborg M et al. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open 2013; 3: e002608.
44. Kudryavtseva AV, Lipatova AV, Zaretsky AR et al. Important molecular genetic markers of colorectal cancer. Oncotarget 2016 in press.
45. Colussi D, Brandi G, Bazzoli F et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013; 14: 16365-16385.
46. Lin JH, Giovannucci E. Environmental exposure and tumor heterogeneity in colorectal cancer risk and outcomes. Curr Colorectal Cancer Rep 2014; 10: 94-104.
47. Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) 2015; 3: 269-276.
48. Kuipers EJ, Grady WM, Lieberman D et al. Colorectal cancer. Nat Rev Dis Primers 2015; 1: 15065.
49. Zong L, Abe M, Ji J et al. Tracking the correlation between CpG island methylator phenotype and other molecular features and clinicopathological features in human colorectal cancers: a systematic review and meta-analysis. Clin Transl Gastroenterol 2016; 7: e151.
50. Pellatt DF, Stevens JR, Wolff RK et al. Expression profiles of miRNA subsets distinguish human colorectal carcinoma and normal colonic mucosa. Clin Transl Gastroenterol 2016; 7: e152.
51. Kedrin D, Gala MK. Genetics of the serrated pathway to colorectal cancer. Clin Transl Gastroenterol 2015; 6: e84.
52. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr 2004; 134: 479-482.
53. Singh N, Gurav A, Sivaprakasam S et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014; 40: 128-139.
54. Donohoe DR, Collins LB, Wali A et al. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 2012; 48: 612-626.
55. Rosty C, Young JP, Walsh MD et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013; 26: 825-834.
56. Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer 2013; 119: 3140-3147.
57. Wong RJ. Marked variations in proximal colon cancer survival by race/ethnicity within the United States. J Clin Gastroenterol 2010; 44: 625-630.
58. Cheng L, Eng C, Nieman LZ et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011; 34: 573-580.
59. Samadder NJ, Curtin K, Tuohy TM et al. Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology 2014; 146: 950-960.
60. Robertson DJ, Lieberman DA, Winawer SJ et al. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut 2014; 63: 949-956.
61. Biedermann L, Zeitz J, Mwinyi J et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One 2013; 8: e59260.
62. O'Keefe SJ, Li JV, Lahti L et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun 2015; 6: 6342.
63. Zitvogel L, Galluzzi L, Viaud S et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med 2015; 7: 271-271.
64. Ogino S, Chan AT, Fuchs CS et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60: 397-411.
65. Ogino S, Nishihara R, VanderWeele TJ et al. Review article: The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 2016; 27: 602-611.
66. Arthur JC, Perez-Chanona E, Muhlbauer M et al. Intestinal inflammation targets cancerinducing activity of the microbiota. Science 2012; 338: 120-123.
67. Wu S, Rhee KJ, Albesiano E et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17T cell responses. Nat Med 2009; 15: 1016-1022.